MS Functional Composite

Objective: The MS Functional Composite (MSFC), a recently developed outcome measure for clinical trials, was applied to 240 patients with MS to explore its utility in different subgroups of MS and for comparison with the Expanded Disability Status Scale (EDSS). Method: Three clinical dimensions were examined: arm/hand function, leg function/ambulation, and cognition. Predictions of relative scores on the MSFC and its components in three major MS phenotypes (relapsing-remitting, primary progressive, and secondary progressive) and three strata of disability were developed and tested. Also, correlations with EDSS were calculated and the effect of an external reference population was assessed. Results: Mean MSFC score was positive in the relapsing-remitting (0.4) and mildly disabled (0.4) groups and negative in the secondary progressive (−0.3), primary progressive (−0.4), and moderately (−0.07) and severely disabled (−1.0) groups. The correlation between EDSS and MSFC was strong (−0.68). EDSS correlated strongly with ambulation in secondary and primary progressive patients and severely disabled patients, moderately with arm/hand function for all analyzed groups, and not at all with cognition. Comparison with an external reference population showed changes in MSFC- and Z-scores, but did not result in altered differences between the subgroups. Conclusion: Our prospective study in subgroups of MS confirmed and extended the construct validity of the MSFC. The MSFC also showed good concurrent validity with the EDSS, and includes information about cognition.

[1]  H. McFarland,et al.  Outcomes assessment in multiple sclerosis clinical trials: a critical analysis , 1995, Multiple sclerosis.

[2]  Christian Confavreux,et al.  Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.

[3]  Richard W. Bohannon.  Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. , 1997, Age and ageing.

[4]  Christian Confavreux,et al.  Recommendations from the national multiple sclerosis society clinical outcomes assessment task force , 1997, Annals of neurology.

[5]  D. Goodkin,et al.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.

[6]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[7]  A. Wiens,et al.  Paced Auditory Serial Addition Test: adult norms and moderator variables. , 1997, Journal of clinical and experimental neuropsychology.

[8]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[9]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[10]  D. McLean,et al.  Methanol poisoning: A clinical and pathological study , 1980, Annals of neurology.

[11]  D. Gronwall.  Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion , 1977, Perceptual and motor skills.

[12]  H. Oesterlé,et al.  Necrosis and haemorrhage of the putamen in methanol poisoning shown on MRI , 1998, Neuroradiology.

[13]  M. Filippi,et al.  Primary Progressive Multiple Sclerosis , 2002, Topics in Neuroscience.

[14]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.